Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: iCAD Inc

Market Cap 106M 91.29M 84.09M 78.77M 148M 10.04B 150M 996M 388M 4.88B 396M 388M 16.91B P/E Ratio 2023
-9.35x
P/E Ratio 2024 -8.59x
Enterprise Value 88.75M 76.73M 70.68M 66.2M 124M 8.44B 126M 838M 326M 4.11B 333M 326M 14.22B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 61 10/03/2023
Director of Finance/CFO 54 17/07/2025
Corporate Secretary - 17/07/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.33%-0.73%+13.00%-10.38% 174B
-0.45%-2.61%-19.87%+31.06% 146B
-0.38%-2.28%-12.19%-24.34% 127B
-0.55%-3.38%-52.40%-8.38% 69.72B
-0.76%-0.99%+12.15%-0.54% 49.01B
+0.67%-0.60%-25.38%-34.31% 44.74B
+0.22%-4.13%+9.19%+9.53% 36.67B
-1.17%-2.69%+1.70%+38.38% 34.91B
+1.04%+0.79%-10.85%-16.72% 29.65B
Average -0.30%-2.10%-9.40%-1.75% 79.13B
Weighted average by Cap. -0.55%-1.98%-8.84%-1.89%

Financials

2023 2024
Net sales 17.32M 14.97M 13.79M 12.92M 24.23M 1.65B 24.59M 163M 63.59M 801M 64.99M 63.61M 2.77B 19.61M 16.95M 15.62M 14.63M 27.43M 1.86B 27.84M 185M 72M 907M 73.58M 72.02M 3.14B
Net income -4.85M -4.19M -3.86M -3.62M -6.78M -461M -6.88M -45.74M -17.8M -224M -18.19M -17.8M -776M -5.62M -4.86M -4.47M -4.19M -7.86M -534M -7.97M -53M -20.62M -260M -21.08M -20.63M -900M
Net Debt -21.21M -18.34M -16.89M -15.82M -29.67M -2.02B -30.11M -200M -77.88M -981M -79.59M -77.9M -3.4B -16.84M -14.56M -13.41M -12.56M -23.56M -1.6B -23.92M -159M -61.85M -779M -63.21M -61.86M -2.7B
Logo iCAD Inc
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!